Post-traumatic stress disorder

Employees Challenged by a Traumatized Workforce Unable to Concentrate; Experts Offer Advice

Retrieved on: 
Thursday, October 14, 2021
Leadership, National Alliance, Prevalence, Fear, Organization, Q4, Solution, The National Alliance, Trauma, Private sector, Work, Risk, ASX, Workplace, TTB, Policy, Attention, Brain, Health, Fatigue, Taft–Hartley Act, Mental health, SAN, Face, Occupation, Health policy, Institute, CEO, Association, Anxiety, Post-traumatic stress disorder, Public sector, Research, Partnership, COVID-19, Meat, Personal protective equipment, Health insurance, Management, Medicine

As areturn to the workplace for many looms large, U.S. employers are faced with a fearful and overwhelmed workforce unable to concentrate.

Key Points: 
  • As areturn to the workplace for many looms large, U.S. employers are faced with a fearful and overwhelmed workforce unable to concentrate.
  • According to experts at One Mind at Work, there are three important steps an employer can take to address trauma.
  • The prevalence of trauma for employees is real, but so are the improvements in focus and resources by employers to support mental health and wellbeing.
  • Collectively, their companies employ more than 10 million employees in the United States, over nine percent of the private sector workforce, and 20 million employees worldwide.

Alto Neuroscience Emerges with Largest Clinical-Stage Precision Psychiatry Pipeline and $40 Million in Financing

Retrieved on: 
Thursday, October 14, 2021
Data science, Factor X, Diagnosis, LOS, Publication, Lists of diseases, National Institute, National Institute of Mental Health, SAB, PTSD, Cognition, AI, Sleep, Brain, Psychiatry, Artificial intelligence, Patient, UTSW, Biology, National, GLOBE, Rafael L. Bras, Mental, Mental health, MDD, EEG, Stanford University, Biomarker, Twitter, Behavior, Post-traumatic stress disorder, Genetics, Risk, NIMH, Pharmaceutical industry, Medical device, Medical imaging

LOS ALTOS, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Alto Neuroscience today announced its emergence from stealth with $40 million in funding to advance the largest clinical-stage pipeline of precision psychiatry medicines. By leveraging its proprietary artificial intelligence (AI)-based brain biomarker platform, the company is advancing 11 clinical-stage assets, with three currently in Phase 2a studies for major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The company anticipates Phase 2 data readouts in these indications for each drug candidate by mid-2023.

Key Points: 
  • Alto is leveraging its deep understanding of brain biology and its AI-enabled brain biomarker platform to advance the largest clinical-stage precision psychiatry pipeline, specifically targeting three key mental health domains: cognition, emotion and sleep.
  • Alto is supported with $40 million in financing raised to date, including a Series A investment led by Apeiron Investment Group.
  • Alto Neuroscience is redefining psychiatry by developing personalized and highly effective medicines to help patients get better faster.
  • The companys clinical-stage pipeline includes drug candidates across three key mental health domains: cognition, emotion and sleep.

VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder

Retrieved on: 
Thursday, October 14, 2021
Instagram, SAD, Central nervous system, Prevalence, Generalized anxiety disorder, CNS, Divorce, Social media, New York State Psychiatric Institute, LinkedIn, Columbia University, Depression, Social anxiety disorder, Post-traumatic stress disorder, Security (finance), Screen for child anxiety related disorders, MOA, Marketing, FDA, Adjustment disorder, Health, Clinical trial, Central nervous system disease, GLOBE, PALISADE, Panic disorder, Mental health, U.S. Securities and Exchange Commission, Benzodiazepine, Company, Anxiety disorder, Fast Track, Annual report, SAN, Hamilton Anxiety Rating Scale, Twitter, Safety, NASDAQ, Therapy, Risk, Principal, COVID-19, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (CNS) disorders, today announced the initiation of a Phase 2A clinical trial to evaluate the efficacy, safety and tolerability of PH94B as a potential treatment of anxiety in adults with Adjustment Disorder with Anxiety (AjDA). In parallel with advancing its ongoing PALISADE Phase 3 clinical program for PH94B in the acute treatment of anxiety in adults with Social Anxiety Disorder (SAD), the Company plans to explore PH94B’s potential in additional anxiety disorders through a series of small Phase 2A trials, the first of which is in AjDA. PH94B is an investigational pherine nasal spray with a unique potential mechanism of action designed to achieve rapid-onset anti-anxiety effects without requiring systemic uptake or causing benzodiazepine-like side effects and safety concerns.

Key Points: 
  • The exploratory Phase 2A clinical trial of PH94B in AjDA is a randomized, double-blind, placebo-controlled study with an enrollment target of approximately 40 adults at clinical sites in the Boston and New York City metro areas.
  • As we continue to advance ongoing Phase 3 clinical development of PH94B in our PALISADE Phase 3 Program in Social Anxiety Disorder, we are excited to launch our Phase 2A clinical program to explore PH94Bs potential in multiple additional anxiety disorders with unmet need, said Shawn Singh, Chief Executive Officer of VistaGen.
  • Expanding on our ongoing efforts to address the alarming prevalence of Social Anxiety Disorder, the initiation of this exploratory Phase 2A study in Adjustment Disorder with Anxiety is an exciting next step toward our goal.
  • In addition, VistaGens exploratory Phase 2A clinical program for PH94B in additional anxiety disorders is now underway with the recent initiation of its Phase 2A clinical trial in AjDA.

Pasithea Therapeutics Opens its First Ketamine Therapy Clinic in the United Kingdom

Retrieved on: 
Thursday, October 14, 2021
ZEN, People, World, Psychopharmacology, Common stock, World Health Organization, Lists of diseases, Nasdaq, Ketamine, Private, MIAMI, Pharmacy, Pharmacist, KTTA, Baker Street, SEC, United Kingdom, Patient, Dermatology, Food and Drug Administration, Holborn, GLOBE, Food, Mental health, Biotechnology, Forward-looking statement, Company, Psychotherapy, CEO, IV, Psychiatry, Nutritionist, Post-traumatic stress disorder, Therapy, Research, Pasithea (Charites), Depression, Anesthesia, Pharmaceutical industry

MIAMI BEACH, Fla., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that its wholly owned subsidiary, Pasithea Clinics, has partnered with ZEN Healthcare to offer intravenous (“IV”) ketamine therapy to patients suffering from treatment-resistant mental health issues. Initially, the treatment will be offered in Knightsbridge, London, beginning October 2021.

Key Points: 
  • Pasithea Clinics has clinic partnerships both in the United States and in the United Kingdom to provide IV ketamine treatment.
  • In the U.S., it has partnered with The IV Doc, Inc., to provide in-home IV ketamine infusions.
  • This launch marks a significant milestone for Pasithea Clinics and for patients in the U.K. suffering with mental health conditions.
  • Our highly trained professionals are taking an integrative approach that combines the IV ketamine infusion therapy with psychiatric support.

Ketamine One Launching Two Inaugural Research Studies

Retrieved on: 
Thursday, October 14, 2021
Science, Veteran, Program, Industry, Ketamine, NEO, OTC, Cannabis, Depression, Pain, ICF, Physician, Health, PTSD, Children's Environmental Exposure Research Study, Institutional review board, KGK, Patient, Chronic pain, Nature, GLOBE, IRB, Mental health, IV, Review, Interim, MEDI, Database, Post-traumatic stress disorder, IRP, Therapy, Pharmaceutical industry

The Research Studies will be conducted across multiple Ketamine One clinic locations in Canada and the United States and are both expected to begin in the month of November.

Key Points: 
  • The Research Studies will be conducted across multiple Ketamine One clinic locations in Canada and the United States and are both expected to begin in the month of November.
  • The launch of these inaugural studies by Ketamine One is a great milestone for our Company and a clear demonstration of the synergies being created between the subsidiaries of KGK Science and IRP Health.
  • These studies represent full collaboration between all our divisions - KGK, IRP Health and our ketamine clinic network.
  • As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

New Analysis Finds St. Louis County, Missouri Had Highest Percentage of Population Screen At-Risk for PTSD of All Large Counties in 2020 and Early 2021

Retrieved on: 
Wednesday, October 13, 2021
Online, Suicidal ideation, BIPOC, LUN, COVID-19, Survivor, Trauma, Environment, Risk, Overalls, Depression, Doctor of Philosophy, Violence, PTSD, Population, MHA, Neurological disorder, Male, GLOBE, Mental health, CEO, Post-traumatic stress disorder, Clifford Whittingham Beers, Psychosis, Female, Medicine, Meat, Animal

PTSD is a mental health condition characterized by ongoing distress that can occur as a response to experiencing or witnessing a traumatic event.

Key Points: 
  • PTSD is a mental health condition characterized by ongoing distress that can occur as a response to experiencing or witnessing a traumatic event.
  • Across the US in 2020 and 2021, 93% scored at-risk when taking a PTSD screen.
  • Our 2020 and 2021 data reflected a significant increase in the rate of those scoring at-risk for PTSD compared to 2019 (84%).
  • Counties: Among large counties, St. Louis County, Missouri (0.029%), had the highest percentage of the population scoring at-risk for PTSD, followed by Franklin County, Ohio (0.026%) and Salt Lake County, Utah (0.026%).

Jefferson Regional and Kindred Healthcare Announce Plans for Inpatient Rehabilitation and Behavioral Health Hospital

Retrieved on: 
Thursday, October 7, 2021
Nursing, Health, Hospitals, Practice Management, Other Health, Managed Care, General Health, National Association Medical Staff Services, Twitter, Post-traumatic stress disorder, LLC, Kindred, Multimedia, Texas Health Resources, Lists of diseases, LinkedIn, Brain, Kindred Healthcare, Health, Depression, Hospital, Stroke, Rehabilitation, Region, Arkansas, Anxiety, Patient, Disability, Bed, Organization, Health insurance

Jefferson Regional and Kindred Healthcare, LLC today announced a joint venture to build and operate a 40-bed freestanding inpatient rehabilitation hospital that will also include an additional 36 behavioral health beds.

Key Points: 
  • Jefferson Regional and Kindred Healthcare, LLC today announced a joint venture to build and operate a 40-bed freestanding inpatient rehabilitation hospital that will also include an additional 36 behavioral health beds.
  • The new hospital will replace and increase the number of existing acute rehabilitation and behavioral health beds currently operating at Jefferson Regional.
  • Jefferson Regional is an acute care hospital in Jefferson County and serves patients from an eleven-county area of Southeast Arkansas.
  • Kindred Healthcare, LLC is the nations leading specialty hospital company delivering acute health services in its long-term, acute care hospitals, including rehabilitation hospitals, acute rehabilitation units, and behavioral health line of business, all specializing in treating the most medically complex patients.

Los Angeles Says: It Ain't Safe to Block Streets and Sidewalks!

Retrieved on: 
Thursday, October 7, 2021
Trauma, Compliance, CAPA, Health, ADA, Disability, HEALTH, CDC, Post-traumatic stress disorder, ACTION, Death, COVID, City, Risk, COVID-19, CALL, Drinking, Suicidal ideation, Safety, AND, ABC, Industry, Pharmaceutical industry, Property insurance

According to an August 2020 CDC report, both African-Americans and Latinx were at dramatically greater risk of trauma or stress disorders related to COVID-19.

Key Points: 
  • According to an August 2020 CDC report, both African-Americans and Latinx were at dramatically greater risk of trauma or stress disorders related to COVID-19.
  • This has manifested in increased suicidal ideation and the initiation of or increase in substance use, as compared to other ethnic or racial groups.
  • Our communities are recovering from the most severe health crisis of our time, expansion of alcohol consumption should not be our priority.
  • California currently suffers over 10,500 alcohol-related deaths, 165,000 alcohol-related hospitalizations and $35 billion in related economic harm annually.

Brain & Behavior Research Foundation Awards Over $10.3 Million In Young Investigator Grants to 150 Mental Health Scientists

Retrieved on: 
Wednesday, October 6, 2021
Borderline personality disorder, Dietary supplement, Gender dysphoria, ADHD, National Institute of Mental Health, Trauma, Psychosis, Emotional and behavioral disorders, Lists of diseases, Brain, Hope, Brain & Behavior Research Foundation, Presidential Young Investigator Award, Young, National academy, Health, Autism, Depression, Adolescence, OCD, Refugee, National Medal of Science, Tic disorder, Mental health, Method, COVID-19 vaccine, CEO, Mother, Risk, National Medal, National Academy of Medicine, COVID-19, National, Post-traumatic stress disorder, Psychiatry, National Institute, Research, PTSD, Pregnancy, Foundation, Bipolar disorder, Anxiety, Schizophrenia, Association, GLOBE, Pharmaceutical industry

New York, Oct. 06, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation today announced its annual Young Investigator Grants, valued at more than $10.3 million, awarded to 150 of the worlds most promising young scientists.

Key Points: 
  • New York, Oct. 06, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation today announced its annual Young Investigator Grants, valued at more than $10.3 million, awarded to 150 of the worlds most promising young scientists.
  • Since 1987, the Foundation has awarded more than $430 million in research grants to more than 5,100 scientists globally.
  • The Brain & Behavior Research Foundation awards research grants to develop improved treatments, cures, and methods of prevention for mental illness.
  • Since 1987, the Foundation has awarded more than $430 million to fund more than 6,200 grants to more than 5,100 leading scientists around the world.

Virpax Signs Agreement with Sinclair Research to Initiate Investigational New Drug (IND)-Enabling Studies for AnQlar™

Retrieved on: 
Wednesday, October 6, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Food, CNS, Nature, Securities Act of 1933, Chronic pain, Research, Epilepsy, CBD, OTC, Regulation of tobacco by the U.S. Food and Drug Administration, Pain management, Central nervous system disease, Security (finance), Drug Quality and Security Act, Sinclair Research, NASDAQ, U.S. Securities and Exchange Commission, FDA, Cancer, Cannabidiol, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Toxicity, Private Securities Litigation Reform Act, Bupivacaine, Coronavirus, Company, MET, Degenerative disease, Pain, COVID-19, Technology, Post-traumatic stress disorder, SARS, Severe acute respiratory syndrome coronavirus 2, PTSD, Cell, Chitosan, Securities Exchange Act of 1934, Industry, Lists of diseases, Vaccine, Pharmaceutical industry, Risk management, AnQlar™, Virpax Pharmaceuticals, ANQLAR™, VIRPAX PHARMACEUTICALS

Virpax Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed an agreement with Sinclair Research, a leading provider of nonclinical research services, to initiate preclinical studies of AnQlar.

Key Points: 
  • Virpax Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed an agreement with Sinclair Research, a leading provider of nonclinical research services, to initiate preclinical studies of AnQlar.
  • AnQlar is being developed by Virpax as a daily over-the-counter (OTC) prophylactic product for treatment against SARS and influenza.
  • Under the terms of this agreement, Sinclair Research will perform preclinical animal studies including method, dosage and toxicity as part of the enabling trials for an Investigational New Drug Application (IND) for AnQlar, as required by the U.S. Food and Drug Administration (FDA).
  • This agreement represents another significant step in the expedited commercialization pathway for AnQlar and is an important milestone in the development of our anti-viral pipeline.